Tvardi Therapeutics Faces Setback as IPF Drug Trial Fails

Tvardi Therapeutics experienced a major setback as its stock dropped significantly following disappointing results from a phase 2 trial for its idiopathic pulmonary fibrosis (IPF) drug. The trial did not meet its goals, raising concerns about the drug's efficacy and the future of treatments for this serious lung disease, impacting both investors and patients seeking new therapies.